Literature DB >> 12576735

Comparison of conjunctival and nasal provocation test in allergic rhinitis to house dust mite.

Herbert Riechelmann1, Barbara Epple, Gunther Gropper.   

Abstract

BACKGROUND: Nasal allergen provocation tests (NPTs) are useful in confirming the diagnosis of allergic rhinitis, if data obtained by clinical history, skin tests and specific IgE determinations are not conclusive. Since NPTs are laborious, conjunctival provocation tests (CPTs) appear as an attractive alternative. The concordance of CPTs and NPTs with house dust mite allergen extract in sensitized and nonsensitized subjects should be evaluated.
METHODS: 50 otherwise healthy subjects with self-reported house dust mite allergy and positive skin prick tests and serum specific IgE to Dermatophagoides pteronyssinus and 45 sex- and age-matched healthy controls without allergic symptoms were included. For NPTs, 100 microl allergen extract [10,000 allergy units (AU/ml)] were applied to the less congested nasal cavity. A clinical symptom score and active anterior rhinomanometry were employed to assess the response. For CPTs, 50 microl low-concentrated D. pteronyssinus extract (1,000 AU/ml), and if negative, 50 microl normally concentrated extract (10,000 AU/ml) were applied to the lower conjunctival sac. The response was assessed employing clinical symptom scores.
RESULTS: NPTs and CPTs yielded concordant results in 90% of the subjects successfully tested (Cohen's kappa = 0.78, p < 0.0001). The diagnostic efficacy of the CPT, with the NPT as the reference method, was 89%, whether or not conjunctival symptoms had been reported in addition to rhinitis symptoms. Both techniques were judged almost equally uncomfortable.
CONCLUSION: CPTs are an acceptable alternative to NPTs in patients with allergic rhinitis to house dust mite, even if they have no conjunctival symptoms. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12576735     DOI: 10.1159/000068369

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  16 in total

1.  Environmental assessment and exposure control of dust mites: a practice parameter.

Authors:  Jay Portnoy; Jeffrey D Miller; P Brock Williams; Ginger L Chew; J David Miller; Fares Zaitoun; Wanda Phipatanakul; Kevin Kennedy; Charles Barnes; Carl Grimes; Désirée Larenas-Linnemann; James Sublett; David Bernstein; Joann Blessing-Moore; David Khan; David Lang; Richard Nicklas; John Oppenheimer; Christopher Randolph; Diane Schuller; Sheldon Spector; Stephen A Tilles; Dana Wallace
Journal:  Ann Allergy Asthma Immunol       Date:  2013-12       Impact factor: 6.347

2.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

3.  Liposomal Eye Spray Is as Effective as Antihistamine Eye Drops in Patients with Allergic Rhinoconjunctivitis Induced by Conjunctival Provocation Testing.

Authors:  Anne-Nele Grzella; Sabine Schleicher; Kija Shah-Hosseini; Anatoli Astvatsatourov; Esther Raskopf; Silke Allekotte; Ralph Mösges
Journal:  Int Arch Allergy Immunol       Date:  2019-03-25       Impact factor: 2.749

4.  [Relevance of nasal provocation testing in house dust mite allergy].

Authors:  B R Haxel
Journal:  HNO       Date:  2017-10       Impact factor: 1.284

5.  Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients.

Authors:  Juliane Rieker-Schwienbacher; Marja J Nell; Zuzana Diamant; Ronald van Ree; Andreas Distler; Johan D Boot; Jörg Kleine-Tebbe
Journal:  Clin Transl Allergy       Date:  2013-05-08       Impact factor: 5.871

6.  Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial.

Authors:  R Mösges; C Bachert; P Panzner; M A Calderon; L Haazen; S Pirotton; N Wathelet; S R Durham; M-A Bonny; T Legon; R von Frenckell; O Pfaar; M H Shamji
Journal:  Allergy       Date:  2018-06-21       Impact factor: 13.146

7.  A controlled challenge study on di(2-ethylhexyl) phthalate (DEHP) in house dust and the immune response in human nasal mucosa of allergic subjects.

Authors:  Tom Deutschle; Rudolf Reiter; Werner Butte; Birger Heinzow; Tilman Keck; Herbert Riechelmann
Journal:  Environ Health Perspect       Date:  2008-07-07       Impact factor: 9.031

8.  A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite-allergic patients.

Authors:  C Hüser; P Dieterich; J Singh; K Shah-Hosseini; S Allekotte; W Lehmacher; E Compalati; R Mösges
Journal:  Allergy       Date:  2016-05-10       Impact factor: 13.146

9.  A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy.

Authors:  R Mösges; E M Kasche; E Raskopf; J Singh; L Sohlich; A Astvatsatourov; K Shah-Hosseini; S Pirotton; L Haazen; S R Durham; T Legon; G Zadoyan; M H Shamji
Journal:  Allergy       Date:  2017-12-22       Impact factor: 13.146

10.  Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy.

Authors:  M Worm; T Higenbottam; O Pfaar; R Mösges; W Aberer; K Gunawardena; D Wessiepe; D Lee; M F Kramer; M Skinner; B Lees; S Zielen
Journal:  Allergy       Date:  2018-06-19       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.